Open Access

Behind and beyond the pediatric metabolic syndrome

Italian Journal of Pediatrics200935:41

DOI: 10.1186/1824-7288-35-41

Received: 3 December 2009

Accepted: 22 December 2009

Published: 22 December 2009

Abstract

The growing use of the Metabolic Syndrome in pediatric age need a critical approach, on the basis of recent concerns on definition and usefulness for individual management in clinical practice. We reviewed these aspects from a pediatric point of view, providing a set of questions about what the Metabolic Syndrome means in a clinical setting. The new proposed pediatric definition by IDF was discussed, by outlying how it does not fully consider the peculiarities of children and adolescents. The comparison between two cases of obese children was used in order to show how this diagnosis could be confusing for a correct management. We stressed the need for health-related limits for each component of the Metabolic Syndrome instead of percentile-derived cut-points, as well as the opportunity to extend the estimation to other family or individual risk factors by means of a multiple-items screening form. In conclusion, Metabolic Syndrome use in pediatric age suffers at present from important limitations (i.e., adult derived definition, possibility to rule-in but not to rule-out the individual metabolic risk, instability of MetS during adolescence, poor usefulness of the diagnosis for specific treatment). Consequently, a prudent use of Metabolic Syndrome for children and adolescents seems to be the best and honest position for paediatricians, waiting for long term, longitudinal follow-up studies that could clarify the entire question.

Introduction

A recent scientific statement from the American Heart Association and other related Committees focussed the topic of the Metabolic Syndrome (MetS) in pediatric age [1]. The paper provided a set of fundamental questions about what the pediatric MetS means in clinical or research setting. The Authors concluded defining limits of our current knowledge and providing suggestions for needed future research [1]. This position paper outlined most of the concerns that pediatricians feel about the usefulness of MetS diagnosis in day by day clinical practice. Concerns also are referred to which MetS definition has to be used for children. Controversies are mainly related to two diverging approaches: one adapting the definition of MetS from adults [24], the other considering the peculiarities of children and adolescents [5, 6].

Aim of the present paper is to discuss difficulties found by pediatricians facing to MetS definition and usefulness.

Discussion

Metabolic syndrome definition

Metabolic syndrome is the clustering of specific metabolic abnormalities found in overweight and obese subjects, but present also in some normal weight subjects. In adults, the presence of three among clinical (obesity or abdominal obesity, hypertension) and metabolic parameters (hyperglycemia, high triglycerides, low HDL-cholesterol) is used to define MetS [24]. In the last decade, many studies in paediatrics derived MetS definition from those used for adults, mostly adapting cut-off points for each parameter to children or adolescents. For this purpose, the percentile methodology was generally used. Recently, the International Diabetes Federation (IDF) proposed a new pediatric definition according to age groups [7]. In particular, IDF suggested that the MetS should not be diagnosed in children younger than 10 yrs, while for subjects 10 to 16 years they proposed the use of adult IDF MetS definition [3] with the only difference represented by waist 90th percentile instead of absolute values. Therefore, the IDF defined a 10-16 yrs old subject as having the MetS if waist circumference was ≥ the 90th percentile and if two other of the following items were above or under a single cut-point: triglycerides ≥ 150 mg/dl, HDL < 40 mg/dl, glucose ≥ 100 mg/dl, systolic or diastolic blood pressure (BP) ≥ 130 or ≥ 85 mmHg, respectively [7].

Despite the pediatric IDF definition is becoming to be used in epidemiological studies [8, 9], pediatricians face these proposed new limits. Glucose cut-point corresponds to that proposed by the American Diabetes Association few years ago with a general agreement [10], as well as the 90th waist circumference percentile is a worldwide considered and accepted limit [11]. On the contrary, the use of single cut-points for high triglycerides and low HDL, independently from the known age- and gender-related variations in this age group, is particularly striking due to the pubertal impact on lipid parameters [12].

Hypertension diagnosis in pediatric age

The most discussed limit among those proposed by IDF is the single blood pressure (BP) cut-point (i.e., 130 for systolic or 85 for diastolic) instead of those related to age, gender and height. Up to now, the risk for hypertension was generally set at the 95th percentile level according to National Health Blood Pressure Education Program (NHBPEP) chart [13]. It appears that the difference between the two limits can be conspicuous, especially for younger subjects with lowest height percentiles, and therefore that a certain degree of underestimation of hypertension could derive from the application of IDF proposal. The main question is whether the pediatrician should prefer the use of single BP limit (130/85), derived from adult clinical surveys and linked to health consequences [14], instead of the use of multiple (up to 84 couple of values in this age interval) age, gender, and height-related limits [13]. However, the latter cumbersome approach seems to be justified by the known variation of BP values in pediatric subjects due to the mentioned variables. At the same time it is striking that an unique BP limit for hypertension risk could work in adult population with subjects of different ages and height ranging even from 150 to 200 cm. In other words, is there an excessive complication of hypertension diagnosis by pediatricians, or a simplification of it for adult doctors, or maybe both? The question remains open. Recently, the discussion on hypertension diagnosis in pediatrics was stimulated by the publication of a simplified table of BP values to be used for screening hypertension risk. This proposal suggested to use, for each age group and gender, the 90th percentile usually applied for shorter children (5th height percentile) [15] in order to avoid undiagnosed hypertension, an approach which seems to take the opposite direction than that of the IDF definition [7]. At the same time, a recent paper together with the accompanying editorial [16, 17] rose other doubts on pediatric hypertension diagnosis, up to now based on normative values instead of on health-related ones. In any case, until this point will be clarified by further longitudinal surveys, it seem preferable for pediatric hypertension diagnosis the use of the more prudent NHBPEP strategy instead of the IDF proposal [7].

Metabolic Syndrome usefulness in clinical practice

In Table 1 we show comparison between 2 obese boys 12 years old with similar excessive BMI and increased waist circumference. The diagnosis of MetS can be done only in the case #1 according to the pediatric definition [7], while in the case #2 we can found the presence of only 2 abnormal parameters. Nevertheless, if we look to other variables not included in the set for MetS, we note that the case #2 shows a clustering of both familial and individual factors which can be considered closely associated with metabolic risk. Recently it was demonstrated the relevant importance of positive family history for type 2 diabetes and other CVD-related diseases in the prediction of future health and risk for MetS [18, 19]. Therefore, we feel that we cannot estimate an higher risk for case #1 respect to case #2 on the basis of the presence of MetS diagnosis alone. Even in the absence of an overt metabolic pattern, as represented by the MetS, the paediatrician should extend the analysis by looking for the presence of other factors (familial or individual) which could confer to that child a potential future risk. We should also highlight the limitations of a dichotomous definition of the MetS, by preferring a continuous indicator [6, 20], or the use of a multiple-items screening form [5].
Table 1

Comparison between 2 cases of 12 years old boys for parameters related to metabolic syndrome and other family or individual risk factors.

 

Case #1

Case #2

BMI*

26.5

26.5

Waist circumference** (cm)

86

85

Glucose (mg/dl)

86

85

Triglycerides (mg/dl)

142

115

HDL cholesterol (mg/dl)

38

42

Blood pressure (mmHg)

136/ 78

132/86

MetS diagnosis, according to [7]

yes

No

Family history for CVD related diseases (in 1st or 2nd degree)

negative

DM2, hypertension, dyslipidemia

Birth weight status

normal

small for gestational age

Early adiposity rebound

no

yes (at 4 years of age)

*BMI as obese according to Cole et al [30]

** Waist circumference values > 90th percentile according to Fernandez et al [11]

Values over or under the cut-points for MetS according to Zimmet et al [7] are reported in bold character.

Taking into consideration MetS diagnosis, we could suggest that its presence in a child could be useful for rule-in but not for rule-out a risk for future health. In fact, there is the possibility of having a false negative estimation in those children not (yet) achieving MetS diagnosis but having other potential factors. In other words, the presence of one cardiovascular risk factor should raise suspicion that additional risk factors may also be present and encourage further investigation [21]. Moreover, it has been proposed that hepatic steatosis should be considered as an additional diagnostic criterion to be added in future approach to this problem [22].

On the other hand we need to consider the clinical value of MetS diagnosis for subject's management. MetS can be considered the clustering of specific conditions and metabolic disorders, but none of them is required to be clinically severe. In fact, the diagnosis can be done by the presence of an increased abdominal adiposity together with pre-hypertension or mild lipid abnormalities, and does not necessarily imply the presence of hypertension, dyslipidemia or reduced glucose tolerance, diseases for which a specific diagnosis is already available. As a consequence of this statement, no specific treatment is strictly necessary in order to manage these findings, except for lifestyle and nutritional changes needed for a correction of excess weight. Therefore, the MetS diagnosis seems not useful for individual treatment, but it can be considered helpful for understanding the possible underlying pathogenesis and for addressing further investigations. Emphasis should be given to the presence of physical inactivity when aiming to estimate the individual metabolic risk, as an impressive mass of data are now confirming the effect of the degree of physical fitness for its prevention in childhood [2327].

Finally, a certain degree of instability has been described in adolescents with MetS during a 3-year observational study in which almost half of previously affected subjects lost their condition [28]. Another recent study confirmed the MetS variability in pediatric age [29].

Conclusions

We must support the need for consensus and further studies on MetS, as stated by the American Heart Association [1]. The main questions to be solved are: 1) is it really safe that a child younger than 10 years should not be diagnosed? 2) which is the clinical cost of considering a 10-16 years adolescent like an adult? 3) is it mandatory to identify cut-points related with future health risk instead of normative ones in pediatric age?

Until these points will be ascertained, we strongly suggest to face the topic of MetS taking into consideration that, at present time, MetS in pediatric age suffers from important limitations (i.e., adult derived definition, possibility to rule-in but not to rule-out the individual metabolic risk, instability of MetS during adolescence, poor usefulness of the diagnosis for specific treatment).

We think that this should be the best and honest position that a paediatrician can now apply to MetS in childhood, waiting for long term, longitudinal follow-up studies that could clarify the entire question.

List of Abbreviations used

MetS: 

metabolic syndrome

HDL: 

high density lipoprotein cholesterol

IDF: 

International Diabetes Federation

BP: 

blood pressure

NHBPEP: 

National Health Blood Pressure Education Program

CVD: 

cardiovascular disease

BMI: 

body mass index

DM2: 

type 2 diabetes

Declarations

Authors’ Affiliations

(1)
ASL Milano 2
(2)
Dipartimento Formazione Permanente, FIMP Federazione Italiana Medici Pediatri
(3)
Pediatric Unit, Verona University Medical School

References

  1. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, Mietus-Snyder ML: Progress and Challenges in Metabolic Syndrome in Children and Adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council of Cardiovascular Disease in the Young; Council on Cardiovascular Nursing, and Council of Nutrition, Physical Activity, and Metabolism. Circulation. 2009, 119: 628-647. 10.1161/CIRCULATIONAHA.108.191394.View ArticlePubMedGoogle Scholar
  2. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. 1999, Geneva, World Health OrgGoogle Scholar
  3. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. [http://www.idf.org]
  4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.Google Scholar
  5. Brambilla P, Lissau I, Flodmark CE, Moreno LA, Widhalm K, Wabitsch M, Pietrobelli A: Metabolic risk-factor clustering estimation in children: to draw a line across pediatric metabolic syndrome. Int J Obes. 2007, 31: 591-600. 10.1038/sj.ijo.0803581.View ArticleGoogle Scholar
  6. Eisenmann JC: On the use of a continuous metabolic syndrome score in pediatric research. Cardiovasc Diabetol. 2008,Google Scholar
  7. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S: The metabolic Syndrome in children and adolescents. Lancet. 2007, 369: 2059-2061. 10.1016/S0140-6736(07)60958-1.View ArticlePubMedGoogle Scholar
  8. Pirkola J, Tammelin T, Bloigu A, Pouta A, Laitinen J, Puokonen A, Tapanainen P, Jarvelin MR, Vaarasmaki M: Prevalence of metabolic syndrome at age 16 using the International Diabetes Federation pediatric definition. Arch Dis Child. 2008, 93: 945-951. 10.1136/adc.2007.132951.View ArticlePubMedGoogle Scholar
  9. Cizmecioglu FM, Etiler N, Hamzaoglu O, Hatun S: Prevalence of metabolic syndrome in schoolchildren and adolescents in Turkey: a population-based study. J Pediatr Endocrinol Metab. 2009, 22: 703-714.View ArticlePubMedGoogle Scholar
  10. American Diabetes Association guideline: Type 2 diabetes in children and adolescents. Diabetes Care. 2000, 23: 381-389. 10.2337/diacare.23.3.381.View ArticleGoogle Scholar
  11. Fernandez JR, Redden DT, Pietrobelli A, Allison DB: Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr. 2004, 145: 439-444. 10.1016/j.jpeds.2004.06.044.View ArticlePubMedGoogle Scholar
  12. Jolliffe JC, Janssen I: Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006, 114: 1056-1062. 10.1161/CIRCULATIONAHA.106.620864.View ArticlePubMedGoogle Scholar
  13. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004, 114: 555-576. 10.1542/peds.114.2.S2.555.View ArticleGoogle Scholar
  14. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360: 1903-1913. 10.1016/S0140-6736(02)11911-8.View ArticlePubMedGoogle Scholar
  15. Kaelber DC, Pickett F: Simple table to identify children and adolescents needing further evaluation of blood pressure. Pediatrics. 2009, 123: e972-e974. 10.1542/peds.2008-2680.View ArticlePubMedGoogle Scholar
  16. Collins RT, Alpert BS: Pre-hypertension and hypertension in pediatrics: don't let the statistics hide the pathology. J Pediatr. 2009, 155: 165-169. 10.1016/j.jpeds.2009.02.006.View ArticlePubMedGoogle Scholar
  17. Flynn JT, Falkner BE: Should the current approach to the evaluation and treatment of high blood pressure in children be changed?. J Pediatr. 2009, 155: 157-158. 10.1016/j.jpeds.2009.03.058.View ArticlePubMedGoogle Scholar
  18. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Berenson GS: Influence of childhood parental history of type 2 diabetes on the pre-diabetic and diabetic status in adulthood: the Bogalusa Heart Study. Eur J Epidemiol. 2009, 24: 537-539. 10.1007/s10654-009-9372-5.View ArticlePubMedGoogle Scholar
  19. Schubert CM, Cook S, Sun SS, Huang TT: Additive utility of family history and waist circumference to body mass index in childhood for predicting metabolic syndrome in adulthood. J Pediatr. 2009, 155 (3): S6-e9-e13.Google Scholar
  20. Thivel D, Malina RM, Isacco L, Aucouturier J, Meyer M, Duché P: Metabolic syndrome in obese children and adolescents: dichotomous or continuous?. Metab Syndr Relat Disord. 2009,Google Scholar
  21. Day C: Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res. 2007, 4: 32-38. 10.3132/dvdr.2007.003.View ArticlePubMedGoogle Scholar
  22. D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, Mohn A: The possible role of liver steatosis in defining metabolci syndrome in prepubertal children. Metabolism. 2009,Google Scholar
  23. Andersen LB, Harro M, Sardinha LB, Froberg K, Ekelund U, Brage S, Anderssen SA: Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). Lancet. 2006, 368: 299-304. 10.1016/S0140-6736(06)69075-2.View ArticlePubMedGoogle Scholar
  24. Eisenmann JC: Aerobic fitness, fatness and the metabolic syndrome in children and adolescents. Acta Paediatrica. 2007, 96: 1723-1729. 10.1111/j.1651-2227.2007.00534.x.View ArticlePubMedGoogle Scholar
  25. Eisenmann JC, Wickel EE, Welk GJ, Blair SN: Association between cardiorespiratory fitness and fatness during adolescence and cardiovascular disease risk factors in adulthood: the Aerobics Center Longitudinal Study. Am Heart J. 2005, 149: 46-53. 10.1016/j.ahj.2004.07.016.View ArticlePubMedGoogle Scholar
  26. Dubose KD, Eisenmann JC, Donnelly JE: Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics. 2007, 120: e1262-e1268. 10.1542/peds.2007-0443.View ArticlePubMedGoogle Scholar
  27. McMurray RG, Bangdiwala SI, Harrell JS, Amorim LD: Adolescents with metabolic syndrome have a history of low aerobic fitness and physical activity levels. Dyn Med. 2008, 7: 5-10.1186/1476-5918-7-5.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Goodman E, Daniels SR, Meigs JB, Dolan LM: Instability in the diagnosis of metabolic syndrome in adolescents. Circulation. 2007, 115: 2316-2322. 10.1161/CIRCULATIONAHA.106.669994.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Gustafson JK, Yanoff LB, Easter BD, Brady SM, Keil MF, Roberts MD, Sebring NG, Han JC, Yanovski SZ, Hubbard VS, Yanovski JA: The stability of metabolic syndrome in children and adolescents. J Clin Endocrinol Metab. 2009,Google Scholar
  30. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition of child overweight and obesity worldwide: international survey. BMI. 2000, 320: 1-6.Google Scholar

Copyright

© Brambilla and Pietrobelli; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement